市場調查報告書

甘露糖-6-磷酸異構酶(MPI)缺損症 - 流行病學預測 2028年

Mannose Phosphate Isomerase (MPI) Deficiency - Epidemiology Forecast to 2028

出版商 DelveInsight Business Research LLP 商品編碼 911518
出版日期 內容資訊 英文 60 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
甘露糖-6-磷酸異構酶(MPI)缺損症 - 流行病學預測 2028年 Mannose Phosphate Isomerase (MPI) Deficiency - Epidemiology Forecast to 2028
出版日期: 2019年09月01日內容資訊: 英文 60 Pages
簡介

主要6個國家(美國、英國、德國、法國、義大利、西班牙)的甘露糖-6-磷酸異構酶(MPI)缺損症的2016年的患病數估計為84人。

本報告提供主要6個國家(美國、英國、德國、法國、義大利、西班牙)的甘露糖-6-磷酸異構酶(MPI)缺損症市場調查,市場概要,疾病概要,以整體及各國患病數的變化與預測詳細彙整。

目錄

第1章 重要洞察

第2章 疾病背景和概要

  • 簡介
  • 概要
  • 病理生理學
  • 原因
  • 症狀
  • 診斷

第3章 流行病學和患者人口

  • 主要調查結果
  • 關鍵意見領袖的意見
  • 主要6個國家的假設和根據

第4章 主要6個國家的甘露糖-6-磷酸異構酶(MPI)缺損症的患病數

第5章 甘露糖-6-磷酸異構酶(MPI)缺損症的流行病學:各國

  • 美國
    • 總診斷患病數
    • 患病數:各臨床症狀
  • 歐洲5個國家
    • 德國
      • 總診斷患病數
      • 患病數:各臨床症狀
    • 法國
      • 總診斷患病數
      • 患病數:各臨床症狀
    • 義大利
      • 總診斷患病數
      • 患病數:各臨床症狀
    • 西班牙
      • 總診斷患病數
      • 患病數:各臨床症狀
    • 英國
      • 總診斷患病數
      • 患病數:各臨床症狀

第6章 附錄

  • 出處

第7章 DelveInsight的服務內容

第8章 免責聲明

第9章 關於DelveInsight

目錄
Product Code: DIEI0382

DelveInsight's 'Mannose Phosphate Isomerase (MPI) Deficiency - Epidemiology Forecast to 2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of MPI in the United States and EU5 (Germany, Spain, Italy, France and United Kingdom).

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)

Study Period: 2016-2028

Mannose Phosphate Isomerase (MPI) Deficiency Epidemiology

The Mannose Phosphate Isomerase (MPI) Deficiency epidemiology division provide the insights about historical and current patient pool and forecasted trend for every six major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and the prevalence based on clinical manifestations in the US and EU5.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total diagnosed prevalent cases, and prevalence based on clinical manifestations) scenario of Mannose Phosphate Isomerase (MPI) Deficiency in the 6MM covering United States and EU5 countries (Germany, Spain, Italy, France and United Kingdom) from 2016-2028.

According to DelveInsight, total prevalent population of Mannose Phosphate Isomerase (MPI) Deficiency in six major markets was found to be 84 in 2016.

Mannose Phosphate Isomerase (MPI) Deficiency Report Insights

  • The report covers detailed overview of Mannose Phosphate Isomerase (MPI) Deficiency explaining its causes, symptoms, pathophysiology, diagnosis and treatment patterns.
  • The report provides the insight about the historical and forecasted patient pool for 6 major markets covering the United States and EU5 (Germany, Spain, France, Italy, and UK).
  • The Report highlights the unmet needs of Iron Overload Disorder (IOD).
  • The Report helps to recognize the growth opportunities in the 6MM with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology by total diagnosed prevalent patient population and clinical manifestations in 6MM.

Mannose Phosphate Isomerase (MPI) Deficiency Report Key Strengths

  • 10 Year Forecast
  • 6MM Coverage
  • Total diagnosed prevalent cases
  • Prevalence of MPI Deficiency based on Clinical Manifestations

Mannose Phosphate Isomerase (MPI) Deficiency Report Assessment

  • Patient Segmentation based on clinical manifestations
  • Disease Risk & Burden
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Disease Background and Overview

  • 2.1 Introduction
  • 2.2 Facts about Mannose Phosphate Isomerase
  • 2.3 Pathophysiology
  • 2.4 Causes
  • 2.5 Symptoms
  • 2.6 Diagnosis

3. Epidemiology and Patient Population

  • 3.1 Key Findings
  • 3.2 KOL's Views: Epidemiology
  • 3.3 Assumptions and Rationale 6MM

4. 6MM Total Prevalent Patient Population of MPI Deficiency

5. Country Wise-Epidemiology of MPI Deficiency

  • 5.1 The United States
    • 5.1.1 Total Diagnosed Prevalent Cases of MPI Deficiency in the United States
    • 5.1.2 Prevalence of MPI Deficiency based on Clinical Manifestations in the United States
  • 5.2 EU5
    • 5.2.1 Germany
      • 5.2.1.1 Total Diagnosed Prevalent Cases of MPI Deficiency in Germany
      • 5.2.1.2 Prevalence of MPI Deficiency based on Clinical Manifestations in Germany
    • 5.2.2 France
      • 5.2.2.1 Total Diagnosed Prevalent Cases of MPI Deficiency in France
      • 5.2.2.2 Prevalence of MPI Deficiency based on Clinical Manifestations in France
    • 5.2.3 Italy
      • 5.2.3.1 Total Diagnosed Prevalent Cases of MPI Deficiency in Italy
      • 5.2.3.2 Prevalence of MPI Deficiency based on Clinical Manifestations in Italy
    • 5.2.4 Spain
      • 5.2.4.1 Total Diagnosed Prevalent Cases of MPI Deficiency in Spain
      • 5.2.4.2 Prevalence of MPI Deficiency based on Clinical Manifestations in Spain
    • 5.2.5 The United Kingdom
      • 5.2.5.1 Total Diagnosed Prevalent Cases of MPI Deficiency in the UK
      • 5.2.5.2 Prevalence of MPI Deficiency based on Clinical Manifestations in The UK

6. Appendix

  • 6.1 Sources Used

7. DelveInsight Capabilities

8. Disclaimer

9. About DelveInsight

List of Tables

Table 1 Prevalent Patient Population of MPI Deficiency in 6MM (2016-2028)

Table 2 Total Diagnosed Prevalent Cases of MPI Deficiency in the US (2016-2028)

Table 3 Prevalence of MPI Deficiency based on Clinical Manifestations in the US (2016-2028)

Table 4 Total Diagnosed Prevalent Cases of MPI Deficiency in Germany (2016-2028)

Table 5 Prevalence of MPI Deficiency based on Clinical Manifestations in Germany (2016-2028)

Table 6 Total Diagnosed Prevalent Cases of MPI Deficiency in France (2016-2028)

Table 7 Prevalence of MPI Deficiency based on Clinical Manifestations in France (2016-2028)

Table 8 Total Diagnosed Prevalent Cases of MPI Deficiency in Italy (2016-2028)

Table 9 Prevalence of MPI Deficiency based on Clinical Manifestations in Italy (2016-2028)

Table 10 Total Diagnosed Prevalent Cases of MPI Deficiency in Spain (2016-2028)

Table 11 Prevalence of MPI Deficiency based on Clinical Manifestations in Spain (2016-2028)

Table 12 Total Diagnosed Prevalent Cases of MPI Deficiency in The UK (2016-2028)

Table 13 Prevalence of MPI Deficiency based on Clinical Manifestations in The UK (2016-2028)

List of Figures

Figure 1 Schematic representation of Mannose Phosphate Isomerase (MPI) key role in glycolysis

Figure 2 Role of Mannose Phosphate Isomerase (MPI) in N-linked glycosylation

Figure 3 Lipid-linked oligosaccharide biosynthetic pathway

Figure 4 Associated Signs and Symptoms of MPI Deficiency

Figure 5 Prevalent Patient Population of MPI Deficiency in 6MM (2016-2028)

Figure 6 Total Diagnosed Prevalent Cases of MPI Deficiency in the US (2016-2028)

Figure 7 Prevalence of MPI Deficiency based on Clinical Manifestations in the US (2016-2028)

Figure 8 Total Diagnosed Prevalent Cases of MPI Deficiency in Germany (2016-2028)

Figure 9 Prevalence of MPI Deficiency based on Clinical Manifestations in Germany (2016-2028)

Figure 10 Total Diagnosed Prevalent Cases of MPI Deficiency in France (2016-2028)

Figure 11 Prevalence of MPI Deficiency based on Clinical Manifestations in France (2016-2028)

Figure 12 Total Diagnosed Prevalent Cases of MPI Deficiency in Italy (2016-2028)

Figure 13 Prevalence of MPI Deficiency based on Clinical Manifestations in Italy (2016-2028)

Figure 14 Total Diagnosed Prevalent Cases of MPI Deficiency in Spain (2016-2028)

Figure 15 Prevalence of MPI Deficiency based on Clinical Manifestations in Spain (2016-2028)

Figure 16 Total Diagnosed Prevalent Cases of MPI Deficiency in The UK (2016-2028)

Figure 17 Prevalence of MPI Deficiency based on Clinical Manifestations in The UK (2016-2028)

Back to Top